The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Recruiting now

A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer

Phase 2 · randomised · 48 people · 1 site in China · Recruiting now

August 8, 2026
Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma

Phase 2 · randomised · 106 people · 1 site in China · Recruiting now

August 8, 2026
Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

Phase 2 · randomised · 54 people · 2 sites in China · Recruiting now

August 8, 2026
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Phase 2 · 534 people · 55 sites in 7 countries · Recruiting now

August 8, 2026
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 2 · 542 people · 82 sites in 4 countries · Recruiting now

August 8, 2026
Tislelizumab in People With Colorectal Cancer

Phase 2 · 40 people · 3 sites in 2 countries · Recruiting now

August 8, 2026
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Phase 2 · randomised · 60 people · 15 sites in United States · Recruiting now

August 8, 2026
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

Phase 2 · randomised · 120 people · 26 sites in 2 countries · Recruiting now

August 8, 2026
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Phase 2 · 300 people · 77 sites in 9 countries · Recruiting now

August 8, 2026
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours

Phase 2 · 454 people · 96 sites in 14 countries · Recruiting now

August 8, 2026